-

Forma Medical Receives U.S. Patent Covering Minimally Invasive Plate Arthrodesis (MIPA™) Methods Across the Foot

CAMP HILL, Pa.--(BUSINESS WIRE)--Forma Medical Inc. announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,751,749, titled “System for Joint Fixation of Extremity Bone and Related Methods.” The patent, which issued October 6, 2026, covers surgical methods for what Forma calls minimally invasive plate arthrodesis, or MIPA™, in which a plate is introduced and secured across a joint of the foot through small incisions rather than a traditional open exposure.

Fusion surgery, or arthrodesis, permanently joins two bones across a joint damaged by arthritis or deformity. It is a mainstay of foot and ankle reconstruction at the big toe, the midfoot, and the hindfoot. Surgeons have long faced a trade-off in how they perform it. Plates provide stable, well-established fixation but have traditionally required a longer incision to implant. Minimally invasive techniques shrink the incision but have typically relied on a screw-only construct. MIPA is designed to remove that trade-off.

The name echoes a shift in fracture care. Since the 1990s, orthopedic trauma surgeons have adopted minimally invasive plate osteosynthesis (MIPO), sliding fracture plates beneath the skin through small incisions to protect the surrounding soft tissue and blood supply. MIPA applies the same principles to joint fusion.

“The fixation surgeons trust, through the small incisions patients ask for. That is what surgeons told us they needed, and MIPA is designed to deliver both,” said Andrew C. Davison, CEO of Forma Medical. “This patent covers the method, not a single implant. The big toe was our starting point, with more than 1,000 procedures to date. The claims extend to other joints of the foot where surgeons already reach for a plate.”

“In urgent fracture care, we have evolved to less invasive surgical approaches for internal fixation, with less anatomic distortion and soft tissue dissection,” said Jesse F. Doty, MD, FAAOS, a fellowship-trained orthopedic foot and ankle surgeon at Integrity Orthopedics and Professor of Orthopaedic Surgery at the University of Tennessee and a co-inventor of the patented technology. “Elective fusion has been slower to progress to an established equivalent until now. MIPA offers a defined, repeatable way to deliver more robust plate fixation through smaller incisions, providing the same benefits we've seen from minimally invasive surgery in other anatomic areas, but without compromised stability. I’ve used MIPA for MTP joint fusions in my own practice for years now. My experience and patient feedback have been highly encouraging, and I plan to submit my clinical outcomes for publication later this year.”

About Forma Medical
Forma Medical Inc. is a privately held orthopedic device company focused on developing differentiated solutions that combine strong biomechanical principles with minimally invasive surgical techniques. The company’s flagship OptimalMTP® system is designed to advance the standard of care in first MTP joint fusion by delivering stability, reproducibility, and efficiency through an MIS approach. OptimalMTP received FDA 510(k) clearance in 2024 and has been used in more than 1,000 procedures.

Contacts

James A. Gault
Forma Medical
support@formamedical.com

Forma Medical Inc.


Release Versions

Contacts

James A. Gault
Forma Medical
support@formamedical.com

More News From Forma Medical Inc.

Forma Medical Announces Strategic Focus on OptimalMTP™, Issuance of Key Methods Patent, and Appointment of Aaron Smith to Board of Directors

CAMP HILL, Pa.--(BUSINESS WIRE)--Forma Medical Inc. announced a sharpened strategic focus on OptimalMTP™, a procedural innovation enabling minimally invasive plating of first metatarsophalangeal (MTP) joint fusion, along with the issuance of a key methods patent and the appointment of Aaron Smith, former CEO of Artelon, to its Board of Directors. The commercial growth of OptimalMTP™ has accelerated since its launch, with demonstrated clinical success in over 650 patients. Building on this clini...

Forma Medical Expands MIS Portfolio; Adds OptimalTMT™, an Innovative, New Lapidus Plating System

CAMP HILL, Pa.--(BUSINESS WIRE)--Forma Medical Inc., a leader in orthopedic Minimally Invasive Surgery (MIS) solutions, today announced the limited market release of OptimalTMT, an innovative MIS Lapidus plating system. OptimalTMT™ builds upon the clinical excellence of OptimalMTP, the MIS MTP fusion plating system, validated by over 200 successful surgeries. “As one of the designers of OptimalTMT, I'm proud that we’ve seamlessly integrated two clinically proven techniques — true minimally inva...

Forma Medical Announces Milestone Achievement: 15th Patient Successfully Treated with OptimalMTP®, the World's First Minimally Invasive Plate and Screw System

CAMP HILL, Pa.--(BUSINESS WIRE)--Forma Medical Inc., a leader in innovative orthopedic solutions, proudly announces the successful treatment of the 15th patient with its groundbreaking OptimalMTP system. The limited release began in August and has now concluded, Forma will now commence broad commercialization of this revolutionary system. The OptimalMTP system is the world's first minimally invasive plate and screw solution for MIS fusion of the first metatarsophalangeal (MTP) joint. The Optima...
Back to Newsroom